The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Falipamil     2-[3-[2-(3,4- dimethoxyphenyl)ethyl- methyl...

Synonyms: Falipamilum, AQ-A-39, AQ-AH-208, AQ-A 39, AQ-AH 208, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AQ-A 39


High impact information on AQ-A 39


Chemical compound and disease context of AQ-A 39


Biological context of AQ-A 39


Anatomical context of AQ-A 39

  • In paced papillary muscle preparations, AQ-A 39 reduced force of contraction only in large doses (1-3 mg) [10].
  • These results show that the bradycardic effects of AQ-A 39 and alinidine are diminished in depolarized preparations, which makes it unlikely that in intact sinus node preparations the mechanism of action is the same as that of "Ca2+-antagonists" [11].
  • In cats with acute occlusion of a coronary artery branch, AQ-A 39 diminished the elevation of the ST-segment of the epicardial electrogram [12].
  • Chronotropic cardiac effects of falipamil in conscious dogs: interactions with the autonomic nervous system and various ionic conductances [13].
  • In the Ba2+ treated depolarized myocardium Vmax was considerably reduced by AQ-A 39 [14].

Associations of AQ-A 39 with other chemical compounds


Gene context of AQ-A 39

  • The parent drug, falipamil (1), and its N-desmethyl-metabolite (2), which is approximately 100 times less active than 1, contributed 14.1 +/- 1.6 and 4.5 +/- 0.7%, respectively, of the dose to urinary excretion [8].

Analytical, diagnostic and therapeutic context of AQ-A 39

  • Beneficial effects of two specific bradycardic agents AQ-A39 (falipamil) and AQ-AH 208 on reversible myocardial reperfusion damage in anesthetized dogs [17].
  • Pharmacokinetics of falipamil in humans (n = 6) was determined in plasma and urine after iv administration of 100 mg (1.85 MBq) per person of 14C-labeled drug by liquid scintillation counting and by a specific, sensitive reversed-phase totally automated HPLC system with fluorimetric detection [8].


  1. Comparison of AQ-A 39 with propanolol and placebo in ischaemic heart disease. Gilfrich, H.J., Oberhoffer, M., Witzke, J. Eur. Heart J. (1987) [Pubmed]
  2. A summary of the acute effects of falipamil in man. Gülker, H. Eur. Heart J. (1987) [Pubmed]
  3. Effect of nifedipine and AQ-A 39 on the sinoatrial and atrioventricular nodes of the rabbit and their antiarrhythmic action on atrioventricular nodal reentrant tachycardia. Senges, J., Rizos, I., Brachmann, J., Anders, G., Jauernig, R., Hamman, H.D., Kübler, W. Cardiovasc. Res. (1983) [Pubmed]
  4. Cardiovascular characterization of UL-FS 49, 1,3,4,5-tetrahydro-7,8-dimethoxy-3-[3-][2-(3,4-dimethoxyphenyl)ethyl] methylimino]propyl]-2H-3-benzazepin-2-on hydrochloride, a new "specific bradycardic agent". Kobinger, W., Lillie, C. Eur. J. Pharmacol. (1984) [Pubmed]
  5. Cardiovascular actions of 5,6-dimethoxy-2-(3-[(alpha-(3,4-dimethoxy) phenylethyl)-methylamino] propyl) phthalimidine (AQ-A 39), a specific bradycardic agent. Dämmgen, J., Kadatz, R., Diederen, W. Arzneimittel-Forschung. (1981) [Pubmed]
  6. Clinical pharmacology of two specific bradycardiac agents. Franke, H., Su, C.A., Schumacher, K., Seiberling, M. Eur. Heart J. (1987) [Pubmed]
  7. Cardiac electrophysiological effects of falipamil in the conscious dog: comparison with alinidine. Boucher, M., Chassaing, C., Chapuy, E. Eur. J. Pharmacol. (1996) [Pubmed]
  8. Pharmacokinetics of falipamil after intravenous administration to humans. Roth, W., Koss, F.W., Hallinan, D., Lambe, R., Darragh, A. Journal of pharmaceutical sciences. (1990) [Pubmed]
  9. Comparison of cardiovascular responses to the bradycardic drugs, alinidine, AQ-A 39, and mixidine, in the anesthetized dog. Siegl, P.K., Wenger, H.C., Sweet, C.S. J. Cardiovasc. Pharmacol. (1984) [Pubmed]
  10. Analyses of the cardiac action of the bradycardic agent, AQ-A 39, by use of isolated, blood-perfused dog-heart preparations. Kawada, M., Satoh, K., Taira, N. J. Pharmacol. Exp. Ther. (1984) [Pubmed]
  11. Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Lillie, C., Kobinger, W. Naunyn Schmiedebergs Arch. Pharmacol. (1984) [Pubmed]
  12. AQ-A 39 (5,6-dimethoxy-2-[3[[alpha-(3,4-dimethoxy)-phenylethyl]methylamino]propyl]phtalimidine), a specific bradycardic agent with direct action on the heart. Kobinger, W., Lillie, C. Eur. J. Pharmacol. (1981) [Pubmed]
  13. Chronotropic cardiac effects of falipamil in conscious dogs: interactions with the autonomic nervous system and various ionic conductances. Boucher, M., Chassaing, C., Chapuy, E., Duchêne-Marullaz, P. J. Cardiovasc. Pharmacol. (1994) [Pubmed]
  14. Electrophysiological studies on effects of AQ-A 39 in the isolated guinea pig heart and myocardial preparations. Hohnloser, S., Weirich, J., Homburger, H., Antoni, H. Arzneimittel-Forschung. (1982) [Pubmed]
  15. Cardiovascular responses to increasing plasma concentrations of AQ-A 39 Cl, a new compound with negative chronotropic effects. Verdouw, P.D., Bom, H.P., Bijleveld, R.E. Arzneimittel-Forschung. (1983) [Pubmed]
  16. Effects of calcium channel blockers on sinoatrial conduction in the isolated and blood-perfused dog atrium. Kobayashi, M., Shimotori, M., Ogiwara, Y., Chiba, S. Archives internationales de pharmacodynamie et de thérapie. (1986) [Pubmed]
  17. Beneficial effects of two specific bradycardic agents AQ-A39 (falipamil) and AQ-AH 208 on reversible myocardial reperfusion damage in anesthetized dogs. Gross, G.J., Daemmgen, J.W. J. Pharmacol. Exp. Ther. (1986) [Pubmed]
WikiGenes - Universities